questionText: To ask the Secretary of State for Health and Social Care, whether he has had discussions with NICE on its Final Draft Guidance which does not recommend CAR-T therapy for relapsed or refractory Mantle Cell Lymphoma.
answerText: Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including in relation to the development of guidance on individual products.NICE develops its recommendations on new ...
heading: Blood Cancer: Medical Treatments